SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 1995 GENZYME CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 0-14680 06-1047163 (State or other jurisdiction (Commission File (IRS Employer of incorporation) Number) Identification No.) One Kendall Square, Cambridge, Massachusetts 02139 (Address of principal executive offices and zip code) Registrant's telephone number, including area code: (617) 252-7500 Item 5. Other Events. ------------ On October 2, 1995, Genzyme Corporation ("Genzyme"), a Massachusetts corporation, completed the acquisition of its majority-owned subsidiary, IG Laboratories, Inc. ("IG"), a Delaware corporation, in a transaction in which IG was merged with and into Genzyme. Genzyme hereby incorporates by reference the contents of its press release dated September 29, 1995, filed as Exhibit 99 to this report. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 11, 1995 GENZYME CORPORATION BY: /s/ Evan M. Lebson ------------------------------------ Evan M. Lebson Vice President, Treasurer EXHIBIT INDEX Exhibit Sequential No. Description Page No. - ------- ----------- ---------- 99 Press release dated September 29, 1995. Filed herewith. 5